English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Acute clinical testing was performed on healthy human subjects to verify whether a single 150mg dose of a proprietary formula marketed under the trade name "Mitochroma TM ” (MCRC) can actually increase blood levels of ATP. Sera and blood were collected immediately prior to treatment and at times 30, 60, and 90 minutes after treatment to measure amounts of blood ATP, lactate, ROS, and pO2. Additionally, whole blood was collected at 270 minutes after treatment to measure expression of selected cytokines and chemokines. In comparison to the placebo group, samples collected from subjects treated with MCRC showed increased levels of total blood ATP by 12.5% on average and reduced levels of lactate up to 13%. Blood levels of ROS and pO2 were found unchanged under these experimental conditions. Analyses of blood collected at 270 minutes showed reduced levels of MCP-1 by up to 21%, and increased levels of Interferonalpha up to 16%. In summary, collected data shows that treatment with a single dose of MCRC resulted in an acute increase in blood levels of total blood ATP. These results justify further clinical studies on MCRC in order to determine the effects on a more narrowly selected subject population with reduced blood levels of ATP and increased blood levels of MCP-1.

Acute Effect of MCRC on Selected Blood Parameters - A Placebo-controlled Acute Clinical Study